AIM: To evaluate metabolic control and health-related quality of life (HRQOL) in a type 1 diabetes mellitus (T1DM) population. METHODS: As part of a prospective cohort study, 283 T1DM patients treated with various insulin treatment modalities including multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII) were examined annually. HRQOL was measured using the SF-36 and EuroQol questionnaires. Data regarding HRQOL, glycaemic and metabolic control from baseline and follow-up measures in 2002 and 2010 were analysed. Linear mixed models were used to calculate estimated values and differences between the three moments in time and the three treatment modalities. RESULTS: Significant changes [mean Δ (95%CI)] in body mass index [2.4 kg/m(2) (1.0, 3.8)], systolic blood pressure [-6.4 mmHg (-11.4, -1.3)] and EuroQol-VAS [-7.3 (-11.4, -3.3)] were observed over time. In 2010, 168 patients were lost to follow-up. Regarding mode of therapy, 52 patients remained on MDI, 28 remained on CSII, and 33 patients switched from MDI to CSII during follow-up. Among patients on MDI, HRQOL decreased significantly over time: mental component summary [-9.8 (-16.3, -3.2)], physical component summary [-8.6 (-15.3, -1.8)] and EuroQol-VAS [-8.1 (-14.0, -2.3)], P < 0.05 for all. For patients using CSII, the EuroQol-VAS decreased [-9.6 (-17.5, -1.7)]. None of the changes over time in HRQOL differed significantly with the changes over time within the other treatment groups. CONCLUSION: No differences with respect to metabolic and HRQOL parameters between the various insulin treatment modalities were observed after 15 years of follow-up in T1DM patients.
AIM: To evaluate metabolic control and health-related quality of life (HRQOL) in a type 1 diabetes mellitus (T1DM) population. METHODS: As part of a prospective cohort study, 283 T1DM patients treated with various insulin treatment modalities including multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII) were examined annually. HRQOL was measured using the SF-36 and EuroQol questionnaires. Data regarding HRQOL, glycaemic and metabolic control from baseline and follow-up measures in 2002 and 2010 were analysed. Linear mixed models were used to calculate estimated values and differences between the three moments in time and the three treatment modalities. RESULTS: Significant changes [mean Δ (95%CI)] in body mass index [2.4 kg/m(2) (1.0, 3.8)], systolic blood pressure [-6.4 mmHg (-11.4, -1.3)] and EuroQol-VAS [-7.3 (-11.4, -3.3)] were observed over time. In 2010, 168 patients were lost to follow-up. Regarding mode of therapy, 52 patients remained on MDI, 28 remained on CSII, and 33 patients switched from MDI to CSII during follow-up. Among patients on MDI, HRQOL decreased significantly over time: mental component summary [-9.8 (-16.3, -3.2)], physical component summary [-8.6 (-15.3, -1.8)] and EuroQol-VAS [-8.1 (-14.0, -2.3)], P < 0.05 for all. For patients using CSII, the EuroQol-VAS decreased [-9.6 (-17.5, -1.7)]. None of the changes over time in HRQOL differed significantly with the changes over time within the other treatment groups. CONCLUSION: No differences with respect to metabolic and HRQOL parameters between the various insulin treatment modalities were observed after 15 years of follow-up in T1DM patients.
Entities:
Keywords:
Continuous subcutaneous insulin infusion; Glycaemic control; Health-related quality of life; Insulin treatment; Multiple daily injections; Type 1 diabetes mellitus
Authors: Hsin-Chieh Yeh; Todd T Brown; Nisa Maruthur; Padmini Ranasinghe; Zackary Berger; Yong D Suh; Lisa M Wilson; Elisabeth B Haberl; Jessica Brick; Eric B Bass; Sherita Hill Golden Journal: Ann Intern Med Date: 2012-09-04 Impact factor: 25.391
Authors: David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman Journal: N Engl J Med Date: 2005-12-22 Impact factor: 91.245
Authors: Nanne Kleefstra; Gijs W D Landman; Sebastiaan T Houweling; Lielith J Ubink-Veltmaat; Susan J J Logtenberg; Betty Meyboom-de Jong; James C Coyne; Klaas H Groenier; Henk J G Bilo Journal: Diabetes Care Date: 2008-03-04 Impact factor: 19.112
Authors: Gijs W D Landman; Kornelis J J van Hateren; Nanne Kleefstra; Klaas H Groenier; Rijk O B Gans; Henk J G Bilo Journal: Diabetes Care Date: 2010-08-30 Impact factor: 17.152
Authors: J G Nunes-Silva; V S Nunes; R P Schwartz; S Mlss Trecco; D Evazian; M L Correa-Giannella; M Nery; M S Queiroz Journal: Nutr Diabetes Date: 2017-01-09 Impact factor: 5.097
Authors: Peter R van Dijk; F Waanders; Jiedong Qiu; Hannah H R de Boer; H van Goor; H J G Bilo Journal: Ther Adv Endocrinol Metab Date: 2020-12-29 Impact factor: 3.565
Authors: C Seguiti; P F Salvo; E Di Stasio; S Lamonica; A L Fedele; S Manfrida; N Ciccarelli; B Corvari; C De Luca; L Tartaglione; D Pitocco; R Cauda; A Cingolani Journal: J Patient Rep Outcomes Date: 2022-03-26
Authors: Peter R van Dijk; Andreas Pasch; Sonja L van Ockenburg-Brunet; Femke Waanders; A Eman Abdulle; Marian J Muis; J L Hillebrands; Henk J G Bilo; Harry van Goor Journal: Ther Adv Endocrinol Metab Date: 2020-02-07 Impact factor: 3.565